Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

Stéphane Oudard,Lionnel Geoffrois,Aline Guillot,Christine Chevreau,Jean-Laurent Deville,Sabrina Falkowski,Helen Boyle,Marjorie Baciuchka,Pierre Gimel,Brigitte Laguerre,Mathieu Laramas,Christian Pfister,Delphine Topart,F. Rolland,Eric Legouffe, Gwénaël Denechere,Eric Yaovi Amela,Sophie Abadie-Lacourtoisie,Marine Gross-Goupil

Annals of oncology : official journal of the European Society for Medical Oncology（2016）

引用 33|浏览26

暂无评分

摘要

•Sunitinib rechallenge in metastatic renal cell carcinoma patients was assessed.•Median PFS was 18.4 and 7.9 months with first-line sunitinib and rechallenge.•Sunitinib rechallenge safety was as expected with no new adverse events reported.•Sunitinib rechallenge is feasible with potential clinical benefit.•Initial progression with sunitinib may not be associated with absolute resistance.

查看译文

关键词

First-line,Metastatic renal cell carcinoma,Rechallenge,Resistance,Sunitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要